The high sensitivity and specificity of the sortilin and syndecan-1 biomarkers offer a significant advantage over PSMA, as the latter has variable expression within cancer tissue and is not overexpressed in all prostate cancers [34]. Here, FOLH1 is linked to prostate cancer.